Polymyalgia Rheumatica Clinical Trials

13 recruiting

Polymyalgia Rheumatica Trials at a Glance

18 actively recruiting trials for polymyalgia rheumatica are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Aarhus, Bonn, and Odense. Lead sponsors running polymyalgia rheumatica studies include University of Bonn, Kresten Krarup Keller, and Centre Hospitalier Universitaire Dijon.

Browse polymyalgia rheumatica trials by phase

Treatments under study

About Polymyalgia Rheumatica Clinical Trials

Looking for clinical trials for Polymyalgia Rheumatica? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Polymyalgia Rheumatica trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Polymyalgia Rheumatica clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Immune Checkpoint InhibitorsArthritisPolymyalgia Rheumatica
M.D. Anderson Cancer Center20 enrolled1 locationNCT06647134
Recruiting
Phase 4

Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency

Adrenal InsufficiencyGiant Cell ArteritisPolymyalgia Rheumatica
Marianne Christina Klose250 enrolled3 locationsNCT05435781
Recruiting
Phase 3

Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)

Polymyalgia Rheumatica
Novartis Pharmaceuticals288 enrolled115 locationsNCT06331312
Recruiting

Rheumatology Patient Registry and Biorepository

Rheumatoid ArthritisLyme DiseaseSarcoidosis+17 more
Yale University5,000 enrolled1 locationNCT04402086
Recruiting
Phase 4

Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment

Adrenal InsufficiencyGiant Cell Arteritis (GCA)Polymyalgia Rheumatica (PMR)
Marianne Andersen100 enrolled3 locationsNCT05193396
Recruiting

Using Novel Imaging to Rethink Diagnostic and Treatment Strategies for Polymyalgia Rheumatica

Polymyalgia Rheumatica (PMR)
Kresten Krarup Keller149 enrolled7 locationsNCT07010484
Recruiting

Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)

Giant Cell Arteritis (GCA)Polymyalgia Rheumatica (PMR)
Centre Hospitalier Universitaire Dijon78 enrolled1 locationNCT06609668
Recruiting

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+10 more
University of Bonn120 enrolled1 locationNCT07150000
Recruiting
Phase 3

Induction and Tapering Therapy With Tofacitinib and Glucocorticoid in Patients With Polymyalgia Rheumatica

Polymyalgia Rheumatica
Zhejiang University98 enrolled1 locationNCT06172361
Recruiting

Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic

Giant Cell ArteritisPolymyalgia Rheumatica
University of Bonn100 enrolled1 locationNCT06460142
Recruiting

AYLo - AutoimmunitY and Loss of y

Asthma BronchialeCOPDSarcoidosis+10 more
University of Bonn500 enrolled1 locationNCT06696027
Recruiting

Predictive Factors for Treatment Response in Patients With Newly-diagnosed Polymyalgia Rheumatica and Giant Cell Arteritis

Giant Cell Arteritis (GCA)Polymyalgia Rheumatica (PMR)
University Hospital, Basel, Switzerland30 enrolled1 locationNCT05479448
Recruiting

Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR)

Giant Cell ArteritisPolymyalgia Rheumatica
University of Leeds4,500 enrolled76 locationsNCT04102930
Recruiting

PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS

Idiopathic Inflammatory MyopathiesGiant Cell ArteritisPolymyalgia Rheumatica+1 more
University Hospital, Brest300 enrolled11 locationsNCT04664465
Recruiting

DANIsh VASculitis Database (DANIVAS)

Giant Cell ArteritisPolymyalgia Rheumatica
Aarhus University Hospital3,000 enrolled2 locationsNCT05935709
Recruiting

Risk of Diabetes Mellitus in Patients With Giant Cell Arthritis and Polymyalgia Rheumatica.

Giant Cell ArteritisPolymyalgia RheumaticaLarge Vessel Vasculitis
Salome Kristensen800 enrolled1 locationNCT06011512
Recruiting

The Australian Arthritis and Autoimmune Biobank Collaborative (A3BC): a national study collecting broad data and biological samples from individuals with arthritis and autoimmune diseases for research towards safer, more effective and evidence-based prevention, diagnosis, treatment and outcome strategies.

Rheumatoid ArthritisAnkylosing SpondylitisScleroderma+9 more
University of Sydney20,000 enrolled36 locationsACTRN12621001564842
Recruiting
Phase 2Phase 3

Treatment of glucocorticoid-induced protein wasting

Long-term glucocorticoid users with polymyalgia rheumatica
St Vincent's Hospital24 enrolled1 locationACTRN12605000642684